Cargando…

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

BACKGROUND: Major prospective randomized clinical safety trials have demonstrated beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose co-transporter-2 inhibitors (SGLT-2i) in people with type 2 diabetes and elevated cardiovascular risk, and rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lugner, Moa, Sattar, Naveed, Miftaraj, Mervete, Ekelund, Jan, Franzén, Stefan, Svensson, Ann-Marie, Eliasson, Björn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983265/ https://www.ncbi.nlm.nih.gov/pubmed/33752680 http://dx.doi.org/10.1186/s12933-021-01258-x

Ejemplares similares

Comparison between data-driven clusters and models based on clinical features to predict outcomes in type 2 diabetes: nationwide observational study
por: Lugner, Moa, et al.
Publicado: (2021)

Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
por: Eliasson, Björn, et al.
Publicado: (2019)

Potential Effects of Bariatric Surgery on the Incidence of Heart Failure and Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus and Obesity and on Mortality in Patients With Preexisting Heart Failure: A Nationwide, Matched, Observational Cohort Study
por: Höskuldsdóttir, Gudrún, et al.
Publicado: (2021)

Treatment persistence in patients with type 2 diabetes treated with glucagon‐like peptide‐1 receptor agonists in clinical practice in Sweden
por: Svensson, Ann‐Marie, et al.
Publicado: (2020)

Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study
por: Svensson, Ann-Marie, et al.
Publicado: (2017)

Efficacy and Safety of Treatment with New Basal Insulin Analogues in Type 1 Diabetes: Nation-Wide Survey
por: Svensson, Ann-Marie, et al.
Publicado: (2020)

Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register
por: Karlsson, Sofia Axia, et al.
Publicado: (2018)

Pros and cons of gastric bypass surgery in individuals with obesity and type 2 diabetes: nationwide, matched, observational cohort study
por: Liakopoulos, Vasileios, et al.
Publicado: (2019)

Clinical Effects and Safety of Direct-Acting Insulin Analogs in Patients with Type 1 Diabetes: A Nation-Wide Observational Cohort Study
por: Lak, Vincent, et al.
Publicado: (2016)

Diabetes mellitus was not associated with lower amputation-free survival after open revascularization for chronic limb-threatening ischemia – A nationwide propensity score adjusted analysis
por: Lilja, Erika, et al.
Publicado: (2021)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

Risk of cardiovascular event and mortality in relation to refill and guideline adherence to lipid-lowering medications among patients with type 2 diabetes mellitus in Sweden
por: Karlsson, Sofia Axia, et al.
Publicado: (2019)

Range of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus
por: Rawshani, Aidin, et al.
Publicado: (2017)

Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study
por: Karlsson, Sofia Axia, et al.
Publicado: (2018)

Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021
por: Malik, Mariam Elmegaard, et al.
Publicado: (2023)

Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR)
por: Ekström, Nils, et al.
Publicado: (2015)

Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden
por: Eliasson, Björn, et al.
Publicado: (2020)

Worse cardiovascular prognosis after endovascular surgery for intermittent claudication caused by infrainguinal atherosclerotic disease in patients with diabetes
por: Dakhel, Ardwan, et al.
Publicado: (2020)

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
por: Goncalves, Edison, et al.
Publicado: (2018)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
por: Sridhar, Vikas S., et al.
Publicado: (2020)

Refill adherence and persistence to lipid‐lowering medicines in patients with type 2 diabetes: A nation‐wide register‐based study
por: Karlsson, Sofia Axia, et al.
Publicado: (2017)

Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register
por: Ekström, Nils, et al.
Publicado: (2013)

Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register
por: Hero, Christel, et al.
Publicado: (2020)

SAT-378 Thyroid Disease, a Severe Infection, and Glucagon Prescription Should Raise the Awareness of Addison's Disease in Patients with Type 1 Diabetes: A National Swedish Study
por: Chantzichristos, Dimitrios, et al.
Publicado: (2019)

Effect of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal observational study of 14,372 flash users compared with 7691 glucose sensor naive controls
por: Nathanson, David, et al.
Publicado: (2021)

Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes
por: Hero, Christel, et al.
Publicado: (2021)

Clinical Use and Effectiveness of Lipid Lowering Therapies in Diabetes Mellitus—An Observational Study from the Swedish National Diabetes Register
por: Eliasson, Björn, et al.
Publicado: (2011)

Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study
por: Simões de Carvalho, Francisco, et al.
Publicado: (2023)

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes
por: Shami, Dalia, et al.
Publicado: (2023)

Blood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study
por: Adamsson Eryd, Samuel, et al.
Publicado: (2016)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

Body mass index as a risk factor for coronary events and mortality in patients with type 1 diabetes
por: Vestberg, Daniel, et al.
Publicado: (2018)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes – a Danish nationwide observational study
por: Falkentoft, Alexander C., et al.
Publicado: (2022)

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
por: Arnold, Suzanne V., et al.
Publicado: (2022)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
por: Winiarska, Agata, et al.
Publicado: (2021)

Effect of Diabetes on Morbidity and Mortality in Patients With Acromegaly
por: Esposito, Daniela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b796qc4578g28amj7ium2n19hu